In this review, the different approaches that have been employed with the aim of developing novel antivenoms against animal envenomings are presented and discussed. Reported efforts have focused on the use of innovative immunization strategies, small molecule inhibitors against enzymatic toxins, endogenous animal proteins with toxinneutralizin capabilities, and recombinant monoclonal antibodies. Harnessing either of these approaches, antivenom development may benefit from an in-depth understanding of venom compositions and which toxins that are essential to neutralize in an envenoming case. Focus is thus also directed towards the different omics technologies (particularly venomics, antivenomics, and toxicovenomics) that are being used to uncover novel animal toxins, shed light on venom complexity, and provide directions for how to determine the medical relevance of individual toxins within whole venoms. Finally, techniques for assessing antivenom specificity and cross-reactivity are reviewed, with special focus on antivenomics and high-density peptide microarray technology. 18 19 59 Neutralization of animal toxins 60 Animal venom toxins are proteinaceous and have evolved primarily to subdue prey, as well as to 61 deter predators. Animal toxins can exert a myriad of different pathophysiological effects in victims 62 of envenoming, including systemic neurotoxicity, haemotoxicity, myotoxicity, and cytotoxicity, 63 manifesting clinically as flaccid paralysis, involuntary muscle contraction, various coagulopathies, 64 nephrotoxicity, and local tissue damage including necrosis [14,15]. Different approaches have been 65 pursued in the attempt to combat different animal venoms and toxins, including the use of novel 66 immunization methods, small molecule inhibitors, endogenous toxin-neutralizing animal proteins, 67 and antibodies. These will be presented in the following. It is, however, beyond the scope of this 68 article to provide an exhaustive review on all the examples of individual antitoxins and novel 69
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In recent year, there has been an increased focus on how to overcome the challenge of snakebite and bring novel antivenoms to poor rural parts of the tropical world. A few reviews are already available in the field (of which I have co-authored some), however, these are focused on the individual efforts and specific toxinneutralizing molecules, antibodies, or sera, and fail to provide an overview of the omics technologies employed to guide their development. Here, I have aimed to provide such an overview, and bring more clarity to how omics technologies interplay with toxinology and how these may be employed to guide medicinal chemistry and biotechnological efforts within antivenom development. It is my personal experience that too many research efforts have been unsuccessful, as they have attempted to develop toxintargeting molecules without taking the complexity of venom and the often inverse relationship between toxicity and immunogenicity into account. It is my belief that an overview of how omics technologies can be harnessed in antivenom development will be useful for particularly drug development researchers (and graduate students) who are new in the field, and who need to gain an understanding of venoms and how these may be viewed and analyzed as drug targets.
I therefore hope that you will take this article into consideration.
Sincerely yours, , which has on several occasions shown to be the case for certain snake venoms from both 172 the viper and elapid families [74-76]. Therefore, genomic and transcriptomic studies may benefit 173 from combination with proteomics to establish a full overview of a venom.
174
The state of the art for elucidation of venom composition is based on the venomics 175 approach, combining venom fractionation by chromatography and gel electrophoresis with mass 176 spectrometry (see Figure 1) technologies emerging within the antibody field allow for more holistic and high-throughput 217 assessments of cross-reactivity.
218
One of the main issues with assessing antibodies by ELISA is that cross-reactivity 219 often correlates poorly with cross-neutralization. As a solution to this, "antivenomics" has been 220 developed based on the same methodology as venomics [95, 96] . In the antivenomics approach, 221 whole venom is pre-incubated with beads coated with antivenom antibodies, before both bound and Figure 2) [97]. This approach, which has so far only been used for 225 serum-based antivenoms, allows for a holistic assessment of the binding capacity of antivenoms 226 against different venom components, which may further be used to assess (potential) cross-227 reactivity to toxins from other snake species that the antivenom was not raised against [78, 96] .
228 Nevertheless, the methodology should, in theory, be just as useful for assessing cross-reactivity of 
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